The true test of their efficacy will be in their ability to reprogram the immunosuppressive features of the TIME and to sustain an immune-activating TIME that will facilitate tumor antigen presentation and the cross-priming of both CD4+ and CD8+ T cells. This evidence concerns the gene CD4 and neoplasm.